Bristol Myers Squibb

New York, New York
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Bristol Myers Squibb (BMS) fired multiple employees who refused to get Covid-19 vaccinations due to religious reasons. BMS settled with those employees after a wrongful termination lawsuit. BMS scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, BMS increases the risk of dividing employees, alienating customers and harming shareholders. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. BMS forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. BMS provides a benefits package for employees which covers travel/lodging costs for an abortion and transgender medical procedures for covered employees and dependents, including children. It is also a corporate partner of Out & Equal and the National LGBT Chamber of Commerce. BMS supports the Equality Act and is a signatory of the Business Roundtable's 2019 Statement on the Purpose of Corporation, which promotes stakeholder capitalism. For these reasons, Bristol Myers Squibb receives a High Risk rating.

View Full Report

Board Bias

Expand Summary

CEO of Bristol Myers Squibb

Chris Boerner, Ph.D.

Chris Boerner, Ph.D.


Headquartered in New York, New York, Bristol Myers Squibb is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Chris Boerner, Ph.D. and Giovanni Caforio, MD serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $180,751 to Republican causes and $173,336 to Democratic causes. Under their tenure, Bristol Myers Squibb currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:





Shareholder Proposals

Expand Summary

ESG Category
Summary of ResolutionMgmt RecTotal Vote % in Favor
5/7/24GovernanceJohn CheveddenExecutives to Retain Significant StockAgainstN/A
5/7/24GovernanceKenneth SteinerIndependent Board ChairmanAgainstN/A
5/2/23GovernanceKenneth SteinerRequire the Chairman of the Board to be an Independent DirectorAgainst31.80%
5/2/23GovernanceJohn CheveddenReduce the Number of Shares Required to Call a Special MeetingAgainst5.90%
5/2/23SocialNational Center for Public Policy ResearchCommission an Audit Analyzing the Impacts of Diversity, Equity, and Inclusion PoliciesAgainst1.60%
5/3/22GovernanceMercy Investment ServicesIndependent Board ChairAgainst44.58%
5/3/22GovernanceKenneth SteinerSpecial Meetings - Reduce Ownership Req. to 10%Against34.33%
Generate Reports